• Neuvotion

  Participated · Equity · Apr 2023

  Neuvotion develops NeuStim™, a technology that combines highly targeted neurostimulation with artificial intelligence to accelerate rehabilitation and make physical and occupational therapy more effective. The company focuses on facilitating and restoring movement for patients impaired by stroke, traumatic injury, and other conditions. Neuvotion plans a multi-site clinical study to begin this year and intends to complete clinical studies using the new funding. Management says it will use the funds to expand its team and pursue FDA clearance for its initial product. Founded by Chad Bouton and based in Darien, CT, Neuvotion is in the early-stage clinical and regulatory phase. The company recently raised additional capital that brings its total funding to $2.75M. Neuvotion is an early-stage medical device company focused on facilitating and restoring movement for patients impaired by stroke, traumatic injury, and other conditions. Its core product, NeuStim™, combines highly targeted neurostimulation and artificial intelligence to make physical and occupational therapy more effective and efficient. The company is led by founder and CEO Chad Bouton and is based in Darien, CT. Neuvotion has received an exclusive worldwide license from Northwell Health for its technology. It raised over $1M in seed funding to advance development and clinical validation, and plans to use the proceeds to expand its team, conduct a multi-site clinical study next year, and pursue FDA clearance for its initial product.

• SetPoint Medical

  Participated · Preferred · Jan 2021

  SetPoint Medical is a commercial-stage medical technology company headquartered in Valencia, Calif., focused on therapies for chronic autoimmune diseases. Its FDA‑approved SetPoint System is the first neuroimmune modulation therapy for adults with moderate-to-severe rheumatoid arthritis, providing a device-based alternative for patients who do not respond to or cannot tolerate biologic or targeted drug therapies. The company’s proprietary integrated neurostimulation platform is designed to activate innate anti-inflammatory pathways in the vagus nerve to reduce inflammation and restore immunologic setpoint. Proceeds from the recent financing will support commercialization of the SetPoint System in select U.S. markets this year and broader national expansion in 2026, and will also fund advancement of the company’s pipeline in other autoimmune conditions. SetPoint plans to evaluate its platform for additional indications including multiple sclerosis and Crohn’s disease. In conjunction with the fundraise the company expanded its leadership team and board to support commercialization and market access efforts. SetPoint Medical is a privately held clinical-stage healthcare company focused on treating chronic autoimmune diseases. The company is developing a novel platform that stimulates the vagus nerve to activate the inflammatory reflex and produce a systemic immune-restorative effect. The SetPoint system is a miniaturized stimulation device placed on the vagus nerve through a small incision on the left side of the neck in an outpatient procedure and delivers stimulation on a preset schedule. The platform is being developed as an alternative for patients with rheumatoid arthritis who have an incomplete response to or are intolerant of biologic drugs, and is also intended for inflammatory bowel disease and other chronic autoimmune conditions. SetPoint is advancing the RESET-RA study and preparing U.S. FDA regulatory submissions and early commercialization for the RA indication. Financially, the company recently announced an $80 million equity financing and expanded a senior secured term loan facility of up to $65 million with Runway Growth Capital to support development and early commercial activities. SetPoint Medical develops a bioelectronic medicine platform designed to stimulate the vagus nerve and activate the body’s inflammatory reflex to produce a systemic immune‑restorative effect for chronic autoimmune diseases. The company is pursuing electrical‑pulse therapies as a potentially safer, lower‑cost alternative to drugs and biologics for conditions including rheumatoid arthritis and inflammatory bowel disease. SetPoint is clinical‑stage and is advancing its technology through the RESET‑RA study, which will evaluate safety and efficacy in patients with moderate‑to‑severe RA. The $35 million financing announced will support the ongoing RESET‑RA trial and other development activities. SetPoint is privately held, was founded in 2007, and is based in Valencia, California. The articles do not disclose revenue or user metrics. SetPoint Medical is a privately held, clinical‑stage bioelectronic medicine company developing a platform that stimulates the vagus nerve to activate the inflammatory reflex and reduce systemic inflammation. The company is initially focused on a less immunosuppressive therapeutic option for patients with rheumatoid arthritis (RA) and is also developing applications for inflammatory bowel disease and other chronic autoimmune conditions. SetPoint’s investigational device is intended to offer an alternative to biologic and targeted drug therapies with potentially lower risk and cost. The company has received Breakthrough Device designation from the U.S. FDA for use in RA patients who are incomplete responders to, or intolerant of, multiple biologic drugs. Proceeds from the financing will support the RESET‑RA multicenter, double‑blind, randomized, sham‑controlled pivotal trial that will enroll up to 250 patients at 40 U.S. sites to evaluate safety and effectiveness. SetPoint converts neurostimulation of the vagus nerve into a systemic immune‑restorative effect and is positioning its platform toward regulatory‑pathway clinical validation. SetPoint Medical is developing a proprietary bioelectronic medicine platform that uses a small implanted device to activate the body’s Inflammatory Reflex and produce a systemic anti-inflammatory effect. The company’s core product is an implanted stimulator that targets the vagus nerve as an alternative to drug therapies for chronic inflammatory diseases. SetPoint has published positive results from a first‑in‑human proof‑of‑concept trial in rheumatoid arthritis in PNAS and presented positive data at the American College of Rheumatology meeting. The company positions its approach as potentially lower risk and lower cost compared with current biologic treatments. SetPoint plans to use the new financing to advance clinical development and enable its next clinical trial in rheumatoid arthritis. It is a privately held company focused on commercializing bioelectronic medicines for debilitating inflammatory diseases.

• Peloton Therapeutics

  Participated · Series E · Feb 2019

  Peloton Therapeutics is a clinical-stage drug discovery and development company focused on first-in-class oral medicines for cancer and other serious conditions. Its lead development program is PT2977, a potent and selective oral HIF-2α inhibitor targeting clear cell renal cell carcinoma and other disorders. The company emphasizes translating novel scientific insights into medicines for debilitating or life‑threatening conditions and notes that HIF-2α was previously thought to be intractable using small molecules. Proceeds from the recent financing will be used to advance Peloton’s research and development pipeline, including PT2977. RA Capital highlighted support as Peloton moves toward a Phase 3 trial of PT2977 for metastatic renal cell carcinoma and advances development in Von Hippel‑Lindau disease. The company issued the announcement from Dallas. Peloton Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule cancer therapies. Its lead programs are inhibitors of hypoxia inducible factor-2α (HIF-2α), a transcription factor implicated in kidney and other cancers. The company emphasizes first-in-class approaches that target unexploited molecular vulnerabilities. Peloton is advancing these programs through clinical development with the aim of impacting renal and other oncology indications. Financially, Peloton recently completed a Series D financing, increasing proceeds to support its programs. The company is publicly identified in the article as based in Dallas. Peloton Therapeutics is a clinical-stage biotech focused on discovering and developing first-in-class small-molecule cancer therapies. Its lead program, PT2385, is a first-in-class small molecule antagonist of hypoxia-inducible factor-2α (HIF-2α). PT2385 has generated reported responses in patients with renal cell carcinoma and is being considered for applications in von Hippel-Lindau disease, glioblastoma multiforme, and other high-unmet-need diseases. The company intends to advance its HIF-2α program and other research programs toward clinical goals. Peloton completed a $52.4 million Series D private financing to support these development plans. Management stated the financing positions the company to realize the full potential of its HIF-2α antagonists and continue its research efforts. Peloton Therapeutics is a Dallas-based early-stage cancer drug discovery and development company focused on small-molecule therapeutics. It is advancing a pipeline of several small molecule-based programs, each with distinct targets and mechanisms of action, in close collaboration with scientists at UT Southwestern. The company was founded by scientist Steven L. McKnight, Ph.D., and its board includes Nobel Laureate Michael S. Brown, John W. Creecy, David V. Goeddel, Tim Kutzkey and Brett A. Ringle. John A. Josey, Ph.D., former Vice President of Discovery Chemistry at Array BioPharma, will join Peloton as President and Chief Scientific Officer. Peloton completed an $18M Series A financing led by The Column Group, with participation from Remeditex Ventures and Peter O’Donnell, Jr. This Series A supplements an $11M grant recently awarded by the Cancer Prevention and Research Institute of Texas (CPRIT).

• ORIC Pharmaceuticals

  Participated · Series C · Feb 2018

  Oric Pharmaceuticals is a clinical-stage oncology company discovering and developing novel therapies targeting treatment-resistant cancers. Its lead asset, ORIC-101, is a potent small-molecule inhibitor of the glucocorticoid receptor (GR) and is the subject of an ongoing Phase 1 study. The company plans to pursue clinical development of ORIC-101 in patients with treatment-resistant solid tumors, including combinations with immuno-oncology therapies and with chemotherapy. The Series C proceeds will support clinical studies of ORIC-101 and research across pipeline programs targeting mechanisms of resistance. After this financing, Oric has raised over $119M in equity capital to date. The company is led by CEO Richard Heyman, Ph.D., CSO Valeria Fantin, Ph.D., and CMO Leonard Reyno, M.D., and was founded by Charles Sawyers, M.D., and Scott Lowe, Ph.D., who are on the faculty at Memorial Sloan Kettering Cancer Center. Oric Pharmaceuticals discovers and develops small‑molecule drugs that target treatment‑resistant cancers. It is initially focusing on resistance mechanisms associated with androgen receptor (AR) therapies in advanced (castration‑resistant) prostate cancer. The company works to gain new clinical understanding of tumor resistance mechanisms at the molecular level and to replicate those mechanisms using laboratory‑based models to identify actionable drug targets with clear development pathways. Oric intends to use the proceeds from its recent financing to advance its first drug candidate into initial clinical trials and to further develop its pipeline. The company raised $53M in a Series B financing to support these plans. Oric was founded by Charles Sawyers, M.D., and Scott Lowe, Ph.D., and is led by interim CEO Richard Heyman, Ph.D., and CSO Valeria Fantin, Ph.D.

• PMV Pharmaceuticals

  Led · Series B · Feb 2017

  PMV Pharmaceuticals is a precision oncology company pioneering the discovery and development of small-molecule, tumor-agnostic therapies targeting p53 mutations. Its mechanism seeks to restore mutant p53 proteins to their normal, wild-type function, which could selectively kill mutant cancer cells without affecting normal tissues. The company leverages over three decades of p53 biology and aims to create potential first-in-class therapies. PMV completed a $70 million Series D to advance its p53 product candidates and expand its pipeline. Management said the proceeds could enable multiple p53 therapies to be advanced into the clinic. PMV is headquartered in Cranbury, New Jersey and announced Rich Heyman, Ph.D., as chair of the board. PMV Pharmaceuticals is developing p53-targeted small molecule drugs and first-in-class p53 regulators for the treatment of cancer. The company focuses on restoring mutant p53, a protein mutated in more than half of all tumors, to activate programmed cancer cell death. PMV is led by President and CEO David Mack, Ph.D., and was co-founded by Dr. Arnold Levine, a discoverer of the p53 protein. The company is based in Cranbury, N.J. PMV intends to use recent financing proceeds to advance its pipeline of mutant p53 restoration drug candidates into the clinic. Its research and development efforts center on translating p53 biology into therapeutics for patients with p53-mutant cancers. PMV Pharmaceuticals is developing first-in-class p53 and p53 pathway modulators as small-molecule therapeutics for cancer. The company was founded by p53 thought leader Arnold Levine and virologist Thomas Shenk and leverages over three decades of p53 biology insight. The articles note p53 is the most commonly mutated protein in human cancers, with more than half of tumors containing mutant p53, which motivates the company’s approach. PMV is advancing a rapidly emerging pipeline of p53-focused programs and intends to use recent financing proceeds to support that advancement. The company emphasizes translating its biological understanding into pharmaceutical development to deliver new medicines to cancer patients. PMV maintains corporate operations in Redwood City, California and research and development in Doylestown, Pennsylvania.

No current team members are available.